Mutations in the kinesin KIF12 promote MASH in humans and mice by disrupting lipogenic enzyme turnover.

Abstract excerpt

As a common cause of liver cirrhosis, metabolic dysfunction-associated steatohepatitis (MASH) is regarded as a target of therapeutic intervention. However, a successful therapy has not yet been found, partly because the molecular pathogenesis is largely elusive. Here we show that KIF12 kinesin suppresses MASH development by accelerating the breakdown of two lipid biosynthesis enzymes, acetyl-CoA carboxylase 1...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acetyl-CoA Carboxylase
• Share to Disease Models, Animal